Advice

following a full submission assessed under the end of life and orphan equivalent medicine process:

amivantamab (Rybrevant®) is not recommended for use within NHSScotland.

Indication under review: in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon20 insertion mutations.

In a phase III study of patients with locally advanced or metastatic NSCLC with EGFR Exon20 insertion mutations, the addition of amivantamab to carboplatin plus pemetrexed significantly improved progression-free survival.

The submitting company’s justification of the treatment’s cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.

Medicine details

Medicine name:
amivantamab (Rybrevant)
SMC ID:
SMC2758
Indication:

In combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon20 insertion mutations.

Pharmaceutical company
Janssen-Cilag Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Not recommended
Date advice published
07 July 2025